Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

heamatology

- PMLiVE

Crunch time as Brexit deal faces ‘meaningful vote’

Rejecting the deal would either result in a no deal or no Brexit, warns May

- PMLiVE

Time running out for ‘no-deal’ Brexit medicines laws

Needs parliament clearance before 29 March

Celgene building

BMS and Celgene announce $74bn merger

Huge news for sector, with new fourth-placed company to be created

- PMLiVE

Dragonfly signs Celgene as partner for NK cell platform

Extends presence in haemato-oncology and solid tumours

Celgene building

ASH18: CAR-T and drugs give new options for multiple myeloma

San Diego congress showcasing data in important haematology markets

- PMLiVE

Shire’s angioedema drug Takhzyro claims EU approval

Approval shortly follows a green light in the US

Innovation in merger control and the impact on the pharmaceutical sector

Is focusing on pipeline products enough to assess regulatory risks?

Celgene building

Celgene to launch five new products through to 2020

Two of which are CAR-T candidates

- PMLiVE

Novartis files for approval of MS drug in EU, US

Siponimod could achieve blockbuster status if approved, says analysts

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

Sanofi reception

Sanofi gets EU OK for Ablynx flagship drug Cablivi

EMA clears the drug to treat adults with aTTP

- PMLiVE

Alnylam gets EU nod for Onpattro amid pricing backlash

However the drug’s price could be lowered in the EU due to direct competition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links